Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Regorafenib, an oral multi-targeted tyrosine kinase inhibitor, is considered the new standardof care in patients with chemotherapy-refractory colorectal cancers (CRCs). However, thereare no data on this drug in Korean patients. Materials and MethodsWe evaluated patients who received oral regorafenib 160 mg once daily during the first 3weeks of each 4-week cycle between August 2013 and September 2013. All patients hadpreviously progressed fluorouracil, irinotecan, and oxaliplatin with or without biologic agentssuch as cetuximab or bevacizumab. ResultsThirty-two patients were enrolled (median age, 57 years; male:female ratio, 20:12; EasternCooperative Oncology Group performance status [0-1:2], 31:1; colon:rectum, 21:11). Theoverall response rate was 3.1% and the disease control rate was 50.0% (95% confidenceinterval [CI]) with one partial response and 15 patients with stable disease. The medianprogression-free survival was 4.2 months (95% CI, 3.1 to 5.2 months) and the medianoverall survival has not yet been reached. The most common adverse events of grade twoor higher related to regorafenib were hand-foot skin reaction (25%), mucositis (19%),abdominal pain (9%), and liver function test (LFT) abnormalities (9%). Grade 3 or 4 toxicitiesincluded LFT abnormalities (9%), abdominal pain (9%), rash (6%), anemia (3%), leukopenia(3%), neutropenic fever (3%), and fatigue (3%). There was no treatment-related death. ConclusionRegorafenib appears to have promising activity and tolerable toxicity profiles in Koreanpatients with refractory CRC, consistent with the CORRECT trial findings.
Abstract
Purpose Regorafenib, an oral multi-targeted tyrosine kinase inhibitor, is considered the new standardof care in patients with chemotherapy-refractory colorectal cancers (CRCs). However, thereare no data on this drug in Korean patients. Materials and MethodsWe evaluated patients who received oral regorafenib 160 mg once daily during the first 3weeks of each 4-week cycle between August 2013 and September 2013. All patients hadpreviously progressed fluorouracil, irinotecan, and oxaliplatin with or without biologic agentssuch as cetuximab or bevacizumab. ResultsThirty-two patients were enrolled (median age, 57 years; male:female ratio, 20:12; EasternCooperative Oncology Group performance status [0-1:2], 31:1; colon:rectum, 21:11). Theoverall response rate was 3.1% and the disease control rate was 50.0% (95% confidenceinterval [CI]) with one partial response and 15 patients with stable disease. The medianprogression-free survival was 4.2 months (95% CI, 3.1 to 5.2 months) and the medianoverall survival has not yet been reached. The most common adverse events of grade twoor higher related to regorafenib were hand-foot skin reaction (25%), mucositis (19%),abdominal pain (9%), and liver function test (LFT) abnormalities (9%). Grade 3 or 4 toxicitiesincluded LFT abnormalities (9%), abdominal pain (9%), rash (6%), anemia (3%), leukopenia(3%), neutropenic fever (3%), and fatigue (3%). There was no treatment-related death. ConclusionRegorafenib appears to have promising activity and tolerable toxicity profiles in Koreanpatients with refractory CRC, consistent with the CORRECT trial findings.
참고문헌 (19)
- Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
- Meyerhardt JA, "Systemic therapy for colorectal cancer", N Engl J Med, 352, pp.476~487 (2005)
- Tournigand C, "FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study", J Clin Oncol, 22, pp.229~237 (2004)
- Kabbinavar FF, "Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer : results of a randomized phase II trial", J Clin Oncol, 23, pp.3697~3705 (2005)
- de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
- Giantonio BJ, "Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin(FOLFOX4)for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200", J Clin Oncol, 25, pp.1539~1544 (2007)
- Van Cutsem E, "Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer", J Clin Oncol, 25, pp.1658~1664 (2007)
- Wilhelm SM, "Regorafenib(BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity", Int J Cancer, 129, pp.245~255 (2011)
- Bruix J, "Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma : multicentre, openlabel, phase II safety study", Eur J Cancer, 49, pp.3412~3419 (2013)
- Schultheis B, "Regorafenib in combination with FOLFOX or FOLFIRI as first-or second-line treatment of colorectal cancer : results of a multicenter, phase Ib study", Ann Oncol, 24, pp.1560~1567 (2013)
- Demetri GD, "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trial", Lancet, 381, pp.295~302 (2013)
- Mross K, "A phase I dose-escalation study of regorafenib(BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors", Clin Cancer Res, 18, pp.2658~2667 (2012)
- Strumberg D, "Regorafenib(BAY 73-4506)in advanced colorectal cancer : a phase I study", Br J Cancer, 106, pp.1722~1727 (2012)
- Grothey A, "Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3trial", Lancet, 381, pp.303~312 (2013)
- Kim ST, "Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer", Asia Pac J Clin Oncol, 7, pp.82~87 (2011)
- Lee DJ, "Salvage S-1monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy", Med Oncol, 28(Suppl 1:), pp.S291~294 (2011)
- Kang EJ, "Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma", Asia Pac J Clin Oncol, 6, pp.286~291 (2010)
- Salgado M, "Gemcitabine and capecitabine as third-or later-line therapy for refractory advanced colorectal cancer : a retrospective study", Anticancer Res, 33, pp.4089~4096 (2013)
- Kim SY, "A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer", Invest New Drugs, 27, pp.269~274 (2009)